BioCardia
BCDA
7 hedge funds and large institutions have $534K invested in BioCardia in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
0.01% less ownership
Funds ownership: 0.16% → 0.16% (-0.01%)
11% less capital invested
Capital invested by funds: $603K → $534K (-$69K)
13% less funds holding
Funds holding: 8 → 7 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$124 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$10.7K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8K |
| 3 |
Millennium Management
New York
|
-$124 |
BCDA Hedge Fund Activity: Q1 2020 in Review
7 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q1 2020, worth a combined $534K — down 11% from $603K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BCDA positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Wells Fargo, opening a new position worth an estimated $124. The largest seller was UBS Group, cutting an estimated $10.7K.
- 7 institutional investors held BioCardia (BCDA) as of Q1 2020, down from 8 in Q4 2019.
- Funds reported $534K of BioCardia stock for Q1 2020, down 11% quarter-over-quarter.
- 2 funds opened new BioCardia positions in Q1 2020 and 1 closed out, a net change of +1 holder.
- The largest BioCardia buyer in Q1 2020 was Wells Fargo, an estimated $124 added.
- The largest BioCardia seller in Q1 2020 was UBS Group, an estimated $10.7K sold.
Based on aggregated 13F filings for Q1 2020.